{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:05:28Z","timestamp":1773932728453,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Municipal Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejps.2025.107407","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:31:34Z","timestamp":1765326694000},"page":"107407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Individualized dosing strategies in breast cancer chemotherapy: Evidence for therapeutic drug monitoring-guided docetaxel treatment"],"prefix":"10.1016","volume":"217","author":[{"given":"Ya-Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Zhe","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Ying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Zhuo","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Ou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-723X","authenticated-orcid":false,"given":"Xiao-Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107407_bib0001","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4155\/bio.10.48","article-title":"Therapeutic drug monitoring in cancer chemotherapy","volume":"2","author":"Bach","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejps.2025.107407_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejon.2008.10.003","article-title":"Docetaxel-related side effects and their management","volume":"13","author":"Baker","year":"2008","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.ejps.2025.107407_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200645030-00002","article-title":"Clinical pharmalcokinetics of docetaxel - recent developments","volume":"45","author":"Baker","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107407_bib0004","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejps.2025.107407_bib0006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpt.128","article-title":"Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window","volume":"98","author":"Coutant","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107407_bib0007","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ajhp\/zxaa128","article-title":"Towards precision medicine: therapeutic drug monitoring-guided dosing of vancomycin and \u03b2-lactam antibiotics to maximize effectiveness and minimize toxicity","volume":"77","author":"Cusumano","year":"2020","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.ejps.2025.107407_bib0008","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-200544020-00002","article-title":"Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation - a review","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107407_bib0009","article-title":"Breast cancer: a review of risk factors and diagnosis","author":"Emmanuel Ifeanyi Obeagu","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.ejps.2025.107407_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/1078-0432.CCR-10-1636","article-title":"Therapeutic drug monitoring for the individualization of Docetaxel dosing: a randomized pharmacokinetic study","volume":"17","author":"Engels","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107407_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.124996","article-title":"Overview of therapeutic drug monitoring and clinical practice","volume":"266","author":"Fang","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.ejps.2025.107407_bib0005","first-page":"21","volume":"46","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.ejps.2025.107407_bib0013","article-title":"Cancer incidence and mortality in China, 2022","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.ejps.2025.107407_bib0014","series-title":"Methods of Therapeutic Drug Monitoring Including Pharmacogenetics","first-page":"291","article-title":"Dose and therapy individualization in cancer chemotherapy","author":"Hempel","year":"2020"},{"key":"10.1016\/j.ejps.2025.107407_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CMAR.S40601","article-title":"Presentation and management of docetaxel-related adverse effects in patients with breast cancer","volume":"6","author":"Ho","year":"2014","journal-title":"Cancer Manage Res."},{"key":"10.1016\/j.ejps.2025.107407_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01126-24","article-title":"Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction","volume":"68","author":"Hu","year":"2024","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejps.2025.107407_bib0017","article-title":"Docetaxel: an update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer","volume":"60","author":"Imran","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejps.2025.107407_bib0018","first-page":"721","volume":"15","author":"Jun","year":"2023"},{"key":"10.1016\/j.ejps.2025.107407_bib0019","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.apsb.2019.10.001","article-title":"Current trends in drug metabolism and pharmacokinetics","volume":"9","author":"Li","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejps.2025.107407_bib0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-023-03604-2","article-title":"Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions","volume":"80","author":"Lin","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107407_bib0021","doi-asserted-by":"crossref","first-page":"105908","DOI":"10.1016\/j.oraloncology.2022.105908","article-title":"Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients","volume":"130","author":"M","year":"2022","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejps.2025.107407_bib0022","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2020.01.76","article-title":"Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients","volume":"8","author":"Ma","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejps.2025.107407_bib0023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bcp.14372","article-title":"Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology","volume":"87","author":"Menz","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107407_bib0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(05)70094-2","article-title":"Docetaxel for treatment of solid tumours: a systematic review of clinical data","volume":"6","author":"Montero","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2025.107407_bib0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2015.04.012","article-title":"Inter-patient variability in docetaxel pharmacokinetics: a review","volume":"41","author":"Nieuweboer","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejps.2025.107407_bib0026","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1590\/S1984-82502015000300007","article-title":"Adverse reactions to docetaxel: an active survey","volume":"51","author":"Pereira","year":"2015","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107407_bib0027","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02394-w","article-title":"Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study","volume":"18","author":"Sun","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejps.2025.107407_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1563506","article-title":"Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients","volume":"16","author":"Tang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107407_bib0029","doi-asserted-by":"crossref","DOI":"10.2174\/0113892002322494240816032948","article-title":"A cross-sectional comparative analysis of eleven population pharmacokinetic models for Docetaxel in Chinese breast cancer patients","author":"Wang","year":"2024","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2025.107407_bib0030","doi-asserted-by":"crossref","DOI":"10.21037\/atm-22-2619","article-title":"Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients","volume":"10","author":"Wei","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejps.2025.107407_bib0031","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2325\/jbcs.13.192","article-title":"Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles","volume":"13","author":"Yip","year":"2006","journal-title":"Breast. Cancer"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500404X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500404X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:37:41Z","timestamp":1773923861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872500404X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"alternative-id":["S092809872500404X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107407","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized dosing strategies in breast cancer chemotherapy: Evidence for therapeutic drug monitoring-guided docetaxel treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107407"}}